Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis

Researchers performed a meta-analysis to assess the efficacy and safety of abemaciclib as monotherapy and in combination with endocrine therapy for HR+ HER2- advanced or metastatic breast cancer. After analyzing 22 studies involving 14,010 patients, the researchers found that abemaciclib significantly improved progression free survival, overall response rate, and overall survival, but it also increased the risk of adverse events in combination with fulvestrant and nonsteroidal aromatase inhibitors. They concluded that abemaciclib appears to be an effective therapeutic option, but it should be used with caution, especially among patients who are treatment naive.